Meta-analysis of diagnostic accuracy of nucleic acid amplification tests for abdominal tuberculosis: A protocol

Shen, Yanqin; Fang, Lingling; Ye, Bo; Yu, Guocan

doi:10.1371/journal.pone.0243765

Cited by 4 publications

(4 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To improve the diagnostic accuracy of TB, researchers continue to develop and innovate new diagnostic techniques, among which NAATs are the shining light. 24 NAATs improve the detection of MTB by amplifying specific gene fragments in MTB DNA or RNA, which can be considered direct microbiological evidence of MTB because it is direct detection of MTB gene fragments. Clinical practice has shown that NAATs effectively improve the detection of TB compared to conventional AFB smears, regardless of PTB or EPTB.…”

Section: Discussionmentioning

confidence: 99%

Comparison of the Diagnostic Accuracy of Xpert MTB/RIF and CapitalBio Mycobacterium RT-PCR Detection Assay for Tuberculous Pericarditis

Yu¹,

Wang²,

Shen³

et al. 2022

IDR

Self Cite

View full text Add to dashboard Cite

Purpose We evaluated CapitalBio Mycobacterium RT-PCR assay diagnosing tuberculous pericarditis (TBP), performed a head-to-head comparison with Xpert MTB/RIF, and assessed the impact of a parallel test (positive result for either of these two tests). Methods We reviewed suspected TBP patients with Xpert MTB/RIF, CapitalBio Mycobacterium RT-PCR assay, and Mycobacterium tuberculosis (MTB) culture. We analyzed sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and area under the curve (AUC). Results Seventy-four patients were included. Overall sensitivity, specificity, PPV, NPV, and AUC of CapitalBio Mycobacterium RT-PCR assay compared with culture were 50%, 91.1%, 64.3%, 85%, and 0.71, respectively. Overall sensitivity, specificity, PPV, NPV, and AUC of Xpert MTB/RIF for TBP were 61.1%, 91.1%, 68.8%, 87.9%, and 0.76. Parallel test values were 72.2%, 91.1%, 72.2%, 91.1%, and 0.82. The diagnostic accuracy of Xpert MTB/RIF was higher than CapitalBio Mycobacterium RT-PCR assay but was not significant ( P > 0.05). The parallel test could improve diagnostic accuracy, but it was not significant compared to single tests ( P > 0.05). Conclusion CapitalBio Mycobacterium RT-PCR assay had a moderate diagnostic accuracy, similar to Xpert MTB/RIF. The parallel test maximized diagnostic efficacy, but differences were not significant. CapitalBio Mycobacterium RT-PCR assay and Xpert MTB/RIF for TBP could be an initial option for early diagnosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Comparison of the Diagnostic Accuracy of Xpert MTB/RIF and CapitalBio Mycobacterium RT-PCR Detection Assay for Tuberculous Pericarditis

Yu¹,

Wang²,

Shen³

et al. 2022

IDR

Self Cite

View full text Add to dashboard Cite

show abstract

“…The statistical heterogeneity between studies will be evaluated by the Q-statistic [ 21 ]. The P -value of the Q-statistic < 0.1 or an I 2 > 50% will be considered as statistically significant heterogeneity between studies [ 22 ]. Data will be analyzed using a fixed-effects model if the heterogeneity is insignificant and a random-effects model if the heterogeneity is significant [ 23 ].…”

Section: Methodsmentioning

confidence: 99%

Neoadjuvant immunotherapy for resectable esophageal cancer: A protocol of meta-analysis

et al. 2021

PLoS ONE

Self Cite

View full text Add to dashboard Cite

Background Esophageal cancer is a highly malignant cancer with a very poor prognosis. For resectable esophageal cancer, neoadjuvant treatment could improve the prognosis of esophageal cancer. However, current clinical neoadjuvant treatment options for esophageal cancer are still limited. The application of immunotherapy is a potentially beneficial new neoadjuvant treatment option for esophageal cancer. The objective of this meta-analysis is to evaluate the efficacy and safety of immunotherapy for the neoadjuvant treatment of esophageal cancer. Methods We will search Wanfang Database, SinoMed, China National Knowledge Infrastructure, Embase, Web of Science, Pubmed, and Cochrane Library for relevant articles published before July, 2021. We will also search the unpublished clinical trials of neoadjuvant immunotherapy in esophageal cancer in preprint website (such as bioRXiv and medRxiv) up to July, 2021. We will perform a meta-analysis to evaluate the efficacy and safety of neoadjuvant immunotherapy for resectable esophageal cancer. Randomized controlled trials (RCTs) will be included in this study. The risk of bias will be evaluated for each included study using the Cochrane Handbook for Systematic Reviews of Interventions. We will use RevMan 5.3 software for statistical analysis of the data. Results The results of this study will provide evidence of immunotherapy using as neoadjuvant treatment for esophageal cancer. This meta-analysis will be submitted to a peer-reviewed journal seeking for publication. Conclusion The results of this study will provide a reliable basis for clinicians and patients to formulate the best pre-surgical treatment plan for resectable esophageal cancer. Systematic review registration INPLASY202120026.

show abstract

“…Q-statistic will be used to evaluate the statistical heterogeneity between studies [ 22 ]. Heterogeneity between studies will be considered statistically significant when the P -value of the Q-statistic is less than 0.1 or an I 2 is greater than 50% [ 23 ]. Data will be analyzed using a fixed-effects model when heterogeneity between studies is insignificant and a random-effects model when heterogeneity between studies was significant.…”

Section: Methodsmentioning

confidence: 99%

Anlotinib-containing regimen for advanced small-cell lung cancer: A protocol of meta-analysis

Cai

et al. 2021

PLoS ONE

Self Cite

View full text Add to dashboard Cite

Background Small cell lung cancer (SCLC) is a highly malignant lung cancer with a very poor prognosis. Clinical treatment options for SCLC are still limited, especially for patients who have failed first or second line therapy. Anlotinib is a potentially beneficial new treatment option for SCLC. The aim of this meta-analysis is to evaluate the efficacy and safety of anlotinib-containing regimen for the treatment of SCLC. Methods We will search SinoMed, Wanfang Database, China National Knowledge Infrastructure, Embase, Cochrane Library, and PubMed for relevant articles that may meet the criteria published before March 31, 2021. We will perform a meta-analysis to evaluate the efficacy and safety of anlotinib-containing regimen for the treatment of SCLC. Clinical randomized controlled trials comparing anlotinib-containing regimens with other treatment regimens for advanced SCLC will be included in this study. The risk of bias will be evaluated for each included study using the Cochrane Handbook for Systematic Reviews of Interventions. We will use RevMan 5.3 software for statistical analysis of the data. Results The results of this study will provide evidence of anlotinib-containing regimens for advanced SCLC, and provide clinicians and patients with another convenient and effective treatment regimen for SCLC. This meta-analysis will be submitted to a peer-reviewed journal for publication. Conclusion This meta-analysis will provide clinical evidence of anlotinib-containing regimens for advanced SCLC, which may or may not be found for anlotinib use. Systematic review registration INPLASY202110034.

show abstract

Meta-analysis of diagnostic accuracy of nucleic acid amplification tests for abdominal tuberculosis: A protocol

Cited by 4 publications

References 10 publications

Comparison of the Diagnostic Accuracy of Xpert MTB/RIF and CapitalBio Mycobacterium RT-PCR Detection Assay for Tuberculous Pericarditis

Comparison of the Diagnostic Accuracy of Xpert MTB/RIF and CapitalBio Mycobacterium RT-PCR Detection Assay for Tuberculous Pericarditis

Neoadjuvant immunotherapy for resectable esophageal cancer: A protocol of meta-analysis

Anlotinib-containing regimen for advanced small-cell lung cancer: A protocol of meta-analysis

Contact Info

Product

Resources

About